Literature DB >> 21172961

The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature.

L Pettit1, A El-Modir.   

Abstract

Thymomas are the most common tumours of the anterior mediastinum; their clinical course is often complicated by accompanying autoimmune and paraneoplastic syndromes. Advanced malignant thymoma is particularly challenging to manage owing to the lack of evidence from randomised trials to guide treatment. Combination first-line chemotherapy has been trialled in several small studies and has been reported to produce a 50-80% response with platinum-containing regimes. Progression following first-line chemotherapy is difficult to manage as most of these patients maintain a good performance status and demand further active palliative treatment. There is no standard second-line treatment. We report a good clinical and radiological response to third-line palliative octreotide therapy in a patient who had a positive octreotide scan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21172961      PMCID: PMC3473811          DOI: 10.1259/bjr/16436465

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  11 in total

Review 1.  Thymoma: state of the art.

Authors:  C R Thomas; C D Wright; P J Loehrer
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 2.  Treatment of malignant thymoma.

Authors:  Giuseppe Giaccone
Journal:  Curr Opin Oncol       Date:  2005-03       Impact factor: 3.645

3.  Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.

Authors:  D Ferone; M P van Hagen; D J Kwekkeboom; P M van Koetsveld; D M Mooy; E Lichtenauer-Kaligis; A Schönbrunn; A Colao; S W Lamberts; L J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

4.  Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.

Authors:  P J Loehrer; M Chen; K Kim; S C Aisner; L H Einhorn; R Livingston; D Johnson
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

5.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.

Authors:  P J Loehrer; M Jiroutek; S Aisner; J Aisner; M Green; C R Thomas; R Livingston; D H Johnson
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

6.  Chemotherapy for invasive thymoma. A 13-year experience.

Authors:  A Fornasiero; O Daniele; C Ghiotto; M Piazza; L Fiore-Donati; F Calabró; F Rea; M V Fiorentino
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

7.  Somatostatin analogs and prednisone in advanced refractory thymic tumors.

Authors:  Giovannella Palmieri; Liliana Montella; Angelo Martignetti; Pietro Muto; Dolores Di Vizio; Annarosaria De Chiara; Secondo Lastoria
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

8.  Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.

Authors:  F Oshita; T Kasai; T Kurata; M Fukuda; N Yamamoto; Y Ohe; T Tamura; K Eguchi; T Shinkai; N Saijo
Journal:  Jpn J Clin Oncol       Date:  1995-10       Impact factor: 3.019

9.  Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

Authors:  P J Loehrer; K Kim; S C Aisner; R Livingston; L H Einhorn; D Johnson; R Blum
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

10.  Follow-up study of thymomas with special reference to their clinical stages.

Authors:  A Masaoka; Y Monden; K Nakahara; T Tanioka
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Thymic neoplasms: a clinical update.

Authors:  Mark Mikhail; Yasmin Mekhail; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

3.  Octreotide in the treatment of malignant thymoma - Case report.

Authors:  Ondrej Sorejs; Milos Pesek; Jindrich Finek; Ondrej Fiala
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.